71. Teva 2015 ($1,200 million)
Israeli drugmaker Teva agreed to pay US$1.2 billion in May 2015 to end a seven-year FTC investigation into allegations that subsidiary Cephalon engaged in anti-competitive practices by preventing rivals from entering the marketplace.
To read more
Subscribe to Global Investigations Review
Subscribe and start reading now
Global Investigations Review (GIR) is the hub for global coverage of corporate investigations and their aftermath. Keep up to date with significant developments in the corporate investigations world.